Press release content from Business Wire. The AP news staff was not involved in its creation.
IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline
May 12, 2021 GMT
DARTMOUTH, Nova Scotia (BUSINESS WIRE) May 12, 2021
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the first quarter ended March 31, 2021.
“We remain focused on our commitment to provide effective and well-tolerated immunotherapies for patients with difficult-to-treat cancers. Clinical programs with our lead immunotherapy are progressing as expected, and we are pleased that maveropepimut-S will soon be evaluated in subjects with HR+/HER2- breast cancer, another unmet medical need,” announced Fred Ors, Chief Executive Officer at IMV. “We are reaching another milestone as our second immunother
Buffalo, N.Y. (PRWEB) May 12, 2021 - Dr. Kalinski has attracted more than $22.5 million in active grants- His innovations have potential to significantly
Graphite Bio Appoints Dr Kristen Hege, Smital Shah and Dr Jo Viney to Board of Directors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Society for Immunotherapy of Cancer Launches Online Seminar Series on Advanced Topics in Immuno-Oncology
Share Article
The Society for Immunotherapy of Cancer (SITC) is pleased to offer a highly anticipated series of live online seminars to address key questions in the field of cancer immunotherapy, both comprehensively and in an easily accessible format. Targets for Cancer Immunotherapy: A Deep Dive is designed for basic, clinical and translational researchers in academia and industry, as well as members of the investment community.
Society for Immunotherapy of Cancer (SITC)
“Many immunotherapy approaches have gained FDA approval in the last ten years; however, the majority of these approvals are for immune checkpoint inhibitors targeting the PD-(L)1 or CTLA-4 pathways,” said SITC President Patrick Hwu, MD.
Posted April 15th, 2021 for OncoSec Medical
April 15, 2021 8:30am EDT PENNINGTON, N.J. and SAN DIEGO, April 15, 2021 / / OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec ), a biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced that it will be presenting encore interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVO™ (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with KEYTRUDA
® (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistant metastatic melanoma patients at the 10
th World Congress of Melanoma. This is an encore presentation of data presented at The Society for Immunotherapy of Cancer s (SITC) 2020 Annual Meeting. Presenters will also discuss the therapeutic potential of OncoSec s DNA medicines platform to elicit robust anti-tumor immunity via intratumoral gene electrotransfer of TAVO plus CXCL9.